Northwestern Genomic Risk Assessment and Management Program
西北基因组风险评估和管理计划
基本信息
- 批准号:10166110
- 负责人:
- 金额:$ 38.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-17 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcute Renal Failure with Renal Papillary NecrosisAwardBiological AssayBloodBlood Coagulation DisordersCOVID-19Clinical DataCollaborationsDevelopmentDiseaseElectronic Medical Records and Genomics NetworkEnzyme-Linked Immunosorbent AssayExposure toFamilyFamily memberGenetic studyGenomicsGenotypeHouseholdImmunoglobulin GIncidenceIndividualInfectionInstitutionKnowledgeMeasuresMyocarditisParentsParticipantPatient RecruitmentsPhasePhenotypePredispositionProphylactic treatmentResearch PersonnelRisk AssessmentRisk ManagementSerologic testsSeveritiesSeverity of illnessSiteSpottingsSymptomsTestingVaccinesValidationWorkbasebiobankdata warehousegenetic analysisgenetic epidemiologyhigh riskpandemic diseasepolygenic risk scoreprogramsreceptor bindingrecruittransmission process
项目摘要
PROJECT SUMMARY
Since early 2020, COVID-19 disease spread rapidly across the US and will likely be sustained or recur
periodically until an effective vaccine or prophylactic treatment is developed. The pandemic will have a large
impact on the conduct of the next phase of eMERGE, including recruitment of new participants as well as
development, validation, and implementation of genomic risk assessments based on polygenic risk scores
(PRS). The supplement presents an opportunity for Northwestern to contribute eMERGE network efforts to
promote the understanding of the genetic epidemiology and individual susceptibility to COVID-19 infection,
disease severity, and complications. In support of efforts proposed in the supplement application for the
coordinating center, we propose to expand Aim 1 of our eMERGE 4 application with the following aim: Create,
validate and implement COVID-19 ePhenotyping for manifest disease, disease severity, and specific
COVID-19 complications in the Northwestern biobank. Recognizing that decisions about ePhenotype
development and implementation will be made in collaboration with the coordinating center and other
participating eMERGE 4 sites, in this supplement, we propose leading phenotype development of three critical
COVID-19 phenotypes 1) myocarditis, 2) acute kidney injury, and 3) coagulopathy complications. Additionally,
we propose to facilitate studies of the full spectrum of COVID-19 disease including those with minimal or no
symptoms, which will motivate participation in eMERGE 4 among individuals who may have been at higher risk
to exposure to COVID-19. To achieve this, we will expand aim 2 of our parent eMERGE 4 application with the
following 2 aims: a) provide SARS-CoV-2 serological testing for IgG to all Northwestern participants
recruited into eMERGE 4 in year 1 of the award and b) facilitate SARS-CoV-2 serology testing and
genotyping of cohabitating family members of eMERGE 4 participants by mail.
项目概要
自 2020 年初以来,COVID-19 疾病在美国迅速传播,并可能持续或复发
定期进行,直到开发出有效的疫苗或预防性治疗方法。此次疫情将产生较大影响
对下一阶段 eMERGE 的影响,包括招募新参与者以及
基于多基因风险评分的基因组风险评估的开发、验证和实施
(PRS)。该增刊为西北航空提供了一个为 eMERGE 网络做出贡献的机会
促进对遗传流行病学和个体对 COVID-19 感染的易感性的了解,
疾病的严重程度和并发症。支持补充申请中提出的努力
协调中心,我们建议扩展 eMERGE 4 应用程序的目标 1,其目标如下:创建、
验证并实施针对明显疾病、疾病严重程度和具体情况的 COVID-19 电子表型分析
西北生物库中的 COVID-19 并发症。认识到有关 ePhenotype 的决定
将与协调中心和其他机构合作制定和实施
参与 eMERGE 4 站点,在本补充材料中,我们建议三个关键的表型发展
COVID-19 表型 1) 心肌炎,2) 急性肾损伤,3) 凝血病并发症。此外,
我们建议促进对全谱 COVID-19 疾病的研究,包括那些症状极少或没有症状的疾病
症状,这将激励可能处于较高风险的个人参与 eMERGE 4
接触 COVID-19。为了实现这一目标,我们将扩展我们的父 eMERGE 4 应用程序的目标 2:
以下 2 个目标:a) 向所有西北参与者提供 SARS-CoV-2 IgG 血清学检测
在获奖第一年招募加入 eMERGE 4,b) 促进 SARS-CoV-2 血清学检测和
通过邮件对 eMERGE 4 参与者的同居家庭成员进行基因分型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
REX L CHISHOLM其他文献
REX L CHISHOLM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('REX L CHISHOLM', 18)}}的其他基金
Northwestern Genomic Risk Assessment and Management Program
西北基因组风险评估和管理计划
- 批准号:
10454926 - 财政年份:2020
- 资助金额:
$ 38.4万 - 项目类别:
Northwestern Genomic Risk Assessment and Management Program
西北基因组风险评估和管理计划
- 批准号:
10207722 - 财政年份:2020
- 资助金额:
$ 38.4万 - 项目类别:
Northwestern Genomic Risk Assessment and Management Program
西北基因组风险评估和管理计划
- 批准号:
10640230 - 财政年份:2020
- 资助金额:
$ 38.4万 - 项目类别:
Genomic Medicine at Northwestern: Discovery and Implementation
西北大学的基因组医学:发现和实施
- 批准号:
9358505 - 财政年份:2015
- 资助金额:
$ 38.4万 - 项目类别:
Genomic Medicine at Northwestern: Discovery and Implementation
西北大学的基因组医学:发现和实施
- 批准号:
9481431 - 财政年份:2015
- 资助金额:
$ 38.4万 - 项目类别:
A Personalized Genomic Medicine Pilot Program Using the NJgene eMERGE Experience
使用 NJgene eMERGE 经验的个性化基因组医学试点计划
- 批准号:
8510804 - 财政年份:2011
- 资助金额:
$ 38.4万 - 项目类别:
A Personalized Genomic Medicine Pilot Program Using the NJgene eMERGE Experience
使用 NJgene eMERGE 经验的个性化基因组医学试点计划
- 批准号:
8319350 - 财政年份:2011
- 资助金额:
$ 38.4万 - 项目类别: